Pharming Group NV (PHARM):企業の財務・戦略的SWOT分析

◆英語タイトル:Pharming Group NV (PHARM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2732
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥16,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥50,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Pharming Group NV (PHARM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Pharming Group NV (Pharming) is a specialty pharmaceutical company which develops nutritional products for the treatment of genetic diseases and unmet medical needs. The company’s flagship product, Ruconest (Rhucin in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema (HAE). Its product pipeline consists of recombinant human C1 inhibitor (rhC1INH) for the treatment of delayed graft function; and recombinant human factor VIII (rhFactor VIII) for the treatment of haemophilia A. The company has manufacturing facilities in the Netherlands and the US. It markets and sells its products through distributors and partners. Pharming is headquartered in Leiden, the Netherlands.

Pharming Group NV Key Recent Developments

Jul 26,2018: Pharming reports on financial results for the first half of 2018
May 17,2018: Pharming Group Interim Report on Financial Results for the First Quarter 2018
Mar 07,2018: Pharming Group Report on Preliminary Financial Results for 2017
Oct 26,2017: Pharming Group reports financial results for the first nine months of 2017
Jul 27,2017: Pharming Reports on Financial Results for the First Half of 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Pharming Group NV – Key Facts 5
Pharming Group NV – Key Employees 6
Pharming Group NV – Key Employee Biographies 7
Pharming Group NV – Major Products and Services 8
Pharming Group NV – History 9
Pharming Group NV – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Pharming Group NV – Business Description 14
Pharming Group NV – Corporate Strategy 15
Pharming Group NV – SWOT Analysis 16
SWOT Analysis – Overview 16
Pharming Group NV – Strengths 16
Pharming Group NV – Weaknesses 17
Pharming Group NV – Opportunities 18
Pharming Group NV – Threats 19
Pharming Group NV – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Pharming Group NV, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Jul 26, 2018: Pharming reports on financial results for the first half of 2018 31
May 17, 2018: Pharming Group Interim Report on Financial Results for the First Quarter 2018 33
Mar 07, 2018: Pharming Group Report on Preliminary Financial Results for 2017 35
Oct 26, 2017: Pharming Group reports financial results for the first nine months of 2017 37
Jul 27, 2017: Pharming Reports on Financial Results for the First Half of 2017 38
May 17, 2017: Pharming Group Interim Report on Financial Results for the First Quarter 2017 43
Mar 09, 2017: Pharming Group: Report on Preliminary Financial Results for 2016 45
Section 6 – Appendix 47
Methodology 47
Ratio Definitions 47
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Pharming Group NV, Key Facts 5
Pharming Group NV, Key Employees 6
Pharming Group NV, Key Employee Biographies 7
Pharming Group NV, Major Products and Services 8
Pharming Group NV, History 9
Pharming Group NV, Subsidiaries 12
Pharming Group NV, Key Competitors 20
Pharming Group NV, Ratios based on current share price 21
Pharming Group NV, Annual Ratios 22
Pharming Group NV, Annual Ratios (Cont...1) 23
Pharming Group NV, Annual Ratios (Cont...2) 24
Pharming Group NV, Interim Ratios 26
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Pharming Group NV, Recent Deals Summary 30
Currency Codes 47
Capital Market Ratios 47
Equity Ratios 48
Profitability Ratios 48
Cost Ratios 49
Liquidity Ratios 49
Leverage Ratios 50
Efficiency Ratios 50

List of Figures
Pharming Group NV, Performance Chart (2013 - 2017) 25
Pharming Group NV, Ratio Charts 27
Pharming Group NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Pharming Group NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

★海外企業調査レポート[Pharming Group NV (PHARM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SCSK Corporation:企業の戦略・SWOT・財務分析
    SCSK Corporation - Strategy, SWOT and Corporate Finance Report Summary SCSK Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Invacare Corporation (IVC):医療機器:M&Aディール及び事業提携情報
    Summary Invacare Corporation (Invacare) is a medical equipment company which develops, manufactures and distributes healthcare products for non-acute care, such as the home healthcare and long term care markets. The major products include power wheelchairs, custom manual wheelchairs, personal mobili …
  • Interconexion Electrica S.A. E.S.P.:発電所・企業SWOT分析
    Interconexion Electrica S.A. E.S.P. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • The Royal Bank of Scotland Group Plc:企業の戦略・SWOT・財務情報
    The Royal Bank of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Pearson plc:企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mapletree Greater China Commercial Trust Management Ltd:企業の戦略・SWOT・財務情報
    Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Greater China Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Nuvia Ltd:企業の戦略的SWOT分析
    Nuvia Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • MedinCell SA:製薬・医療:M&Aディール及び事業提携情報
    Summary MedinCell SA (MedinCell) is a developer of therapeutic solutions for the healthcare market. The company develops and commercializes BEPO, a technology based on custom proprietary copolymers and a biocompatible solvent for long acting injectables. Its BEPO provides a controlled release of the …
  • Take-Two Interactive Software, Inc.:企業の戦略・SWOT・財務分析
    Take-Two Interactive Software, Inc. - Strategy, SWOT and Corporate Finance Report Summary Take-Two Interactive Software, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Vexim SA (ALVXM):企業の財務・戦略的SWOT分析
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • Hwange Colliery Co Ltd:企業の戦略・SWOT・財務分析
    Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • St. George Bank Limited:企業の戦略・SWOT・財務情報
    St. George Bank Limited - Strategy, SWOT and Corporate Finance Report Summary St. George Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Klepierre SA:企業のM&A・事業提携・投資動向
    Klepierre SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Klepierre SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • State Oil Company of the Azerbaijan Republic:石油・ガス:M&Aディール及び事業提携情報
    Summary State Oil Company of the Azerbaijan Republic (SOCAR) is an oil and gas exploration company. The company explores oil and gas fields; and produces, processes and transports oil, gas and gas condensate. It markets petroleum and petrochemical products in domestic and international markets and s …
  • Challenger Ltd.:企業の戦略・SWOT・財務情報
    Challenger Ltd. - Strategy, SWOT and Corporate Finance Report Summary Challenger Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Syndax Pharmaceuticals Inc (SNDX):製薬・医療:M&Aディール及び事業提携情報
    Summary Syndax Pharmaceuticals Inc (Syndax) is a biopharmaceutical company that develops and commercializes therapies for multiple cancer indications. The company’s lead product candidate includes entinostat, an oral, small molecule drug candidate, which is in phase 3 clinical trial used for the tre …
  • Grupo Aeroportuario del Sureste SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Sureste SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Sureste SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • adidas AG (ADS):企業の財務・戦略的SWOT分析
    adidas AG (ADS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PT Pembangkitan Jawa-Bali:企業の戦略的SWOT分析
    PT Pembangkitan Jawa-Bali - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆